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Abstract 
Most published reports of patient safety in clinical practice focus largely on the culture of safety in complex health systems, separate 
from pre-approval and postmarketing research-related safety considerations for drugs, biologics, and other medical products. The 
science of safety requires a linked integrated perspective, i.e., an iterative process examining and relating safety concerns from drug 
or biologic discovery and development in preclinical stages, clinical trials and post-market use, research, surveillance, and potential 
regulatory changes. This commentary addresses the science of safety across the lifecycle of drug and biological products, regulatory 
considerations, barriers, and research needs. This paper provides a brief overview on how the functioning of healthcare systems 
affects the safety environment and describes how stakeholder involvement, research participation, and targeted education and 
training can help facilitate better safety measures and practices, provide improved quality of care to patients, and contribute to the 
science of safety. 
 
 
Science of Safety along the Lifecycle  
The emerging concept of the science of safety is new to most 
pharmacists, physicians and other clinicians.  Our 
conceptualization of the science of safety for medication use 
is envisaged as a linked and iterative process along the 
lifecycle of prescribed drugs and biologics in Figure 1.1-17 The 
distinguishing feature of the science of safety is its all-
encompassing, systematic lifecycle approach to drug safety, 
rather than focusing on separated knowledge spheres. 
Combined efforts in the science of safety are needed to 
decrease adverse drug events -- both serious adverse drug 
reactions and medication errors.18  
 
The science of safety for medication use aims at methods to 
prevent adverse events by targeting use of specific agents for 
patients in whom benefits are maximized over risks and 
identifying safety concerns quickly.2,3,16 Across the lifecycle of 
drugs, the framework of the science of safety incorporates 
advances in toxicology screenings, pharmacogenetics, and 
pharmacogenomics with the envisioned goals of effective 
treatment and reduced drug toxicity in providing 
personalized medicine to diverse patient populations. The 
science of safety includes disease awareness of molecular 
medicine (recognizing promising therapeutic benefits and 
adverse risks) and novel methods of signaling, data mining 
and analysis for drug/biologic safety.14  It enables hypothesis 
generation about the existence and causes of safety problems 
and exploration of genetics and biomarkers that may help 
promote individualized drug treatment regimens.14,16,19 The  
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science of safety calls for a transformational, team-oriented,  
multidisciplinary approach in delivering high quality of care 
and improving patient safety. This involves preclinical and 
clinical studies, regulatory review, postmarketing 
surveillance, and risk management. The science of safety also 
considers human factors, organizational cultures, informatics, 
and clinical practices and communications that help guide 
clinical treatment, regulatory decisions, and research through 
effective communications, programs, and processes.2,6,10,12,14  
 
Since the 1999 publication of To Err is Human by the Institute 
of Medicine (IOM),20 progress in achieving safer healthcare 
systems has been noted 5-years,21,22 10-years,23,24 and 15 
years25 following the landmark report. Progressive awareness 
of patient safety considerations is increasingly conceptualized 
through a “total systems approach” involving providers and 
engaged consumers, rather than less deliberative piecemeal 
interventions.25,26 Despite efforts such as root cause analysis 
in healthcare systems and implementing interventions to 
reduce risks, occurrence of sentinel adverse events persist. 
The initiatives and goals proposed by IOM in 1999 are 
commendable although the healthcare system has lacked 
strategic models and tailored mechanisms to achieve them.21 
The concept of the science of safety is not necessarily 
individually driven but involves a system driven approach to 
bring about changes in the current healthcare system and 
implementation of new health quality forums. Tremendous 
impact of transformative change could be witnessed when 
the concept is viewed by a single vision with the prime 
motives of patient safety and better quality care.1,6  
 
Drug approval and regulation 
In drug and biological product approval and postmarketing 
surveillance efforts, the U.S. Food and Drug Administration 
(FDA) determines safety and effectiveness. The Agency also 
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considers optimal trade-offs with respect to access, risk, and 
value in product use for labeled indications in specified 
populations. The FDA Amendments Act of 2007 (FDAAA)27 
provided mechanisms for more resources to facilitate the 
science of safety across the lifecycle of drugs, biologics and 
devices.11 Implementation of Title IX of FDAAA on March 25, 
2008 enhanced FDA’s authority in post-market drug safety 
initiatives including expanded Risk Evaluation and Mitigation 
Strategies (REMS), postmarketing studies/clinical trials and 
surveillance, and safety-related labeling changes.28-30 REMS 
plans (updated list available online31) allow drug/drug classes 
or biologics with serious safety risks to be approved for 
marketing or to remain available on the market for patients 
who could benefit from them. Implementation and 
management of REMS, specifically those with Elements to 
Assure Safe Use (ETASU), can exact a burden on healthcare 
practitioners due to the lack of standardization and time-
consuming nature of the requirements.29 ETASU include 
training or specific certification of prescribers; certification of 
pharmacists or other practitioners and/or pharmacies or 
other dispensing sites; restricted dispensing outlets; 
dispensing under conditions of safe use such as required 
laboratory testing; patient monitoring; and/or enrollment of 
each patient in a registry. Stakeholder feedback regarding 
experiences with REMS/ETASU and associated challenges is 
encouraged by FDA and would build upon the iterative 
science of safety process. 
   
FDA plays an important role in mitigating medication risks 
and identifying risks for preventable errors that can occur at 
any point in the complex U.S. healthcare system.14 
Stakeholder involvement is crucial as it increases 
transparency and communication32 and helps maintain 
scientific integrity and credibility. Stakeholders also help 
disseminate information produced through research, and 
their role towards science of safety is illustrated in Figure 2. 
The Agency’s intersection with the industry, healthcare 
providers, and other governmental public health agencies 
help enable FDA to facilitate this collaborative process. 
Examples of stakeholders for FDA in the science of safety 
include:  
 
• pharmaceutical industry; federal agencies, such as the 
Drug Enforcement Administration (DEA), the Agency for 
Healthcare Research and Quality (AHRQ), the Centers 
for Disease Control and Prevention (CDC), and the 
Centers for Medicare and Medicaid Services (CMS);  
healthcare professionals and their professional 
societies; patients and patient advocates (including 
consumer groups), and others.  
 
 
 
Healthcare Systems 
Transitioning to safer healthcare practices requires that 
healthcare practitioners understand the challenges faced in 
complex healthcare environments, human factors 
contributions to adverse events, qualities of “high reliability 
organizations” and other resources for patient safety.33 With 
the escalating demand to ensure safety, quality, efficacy and 
efficiency, it becomes essential for interdisciplinary 
healthcare teams to collectively share the common goal of 
patient safety.34,35 Problematic professional relationships and 
communication gaps among health professionals have an 
impact on the quality of care provided.36-38 For example, in 
physician-nurse interactions, doctors tend to perceive good 
working relationships more often than do nurses, possibly 
due to lack of understanding about challenges nurses face in 
hierarchical system roles.36 Inadequate collaboration and 
communication is also seen between physicians and 
administrators, as well as physicians and pharmacists. When 
provided with access to data-rich environments (e.g., 
electronic medical records) and identifying preferred contact 
modes (e.g., fax, telephone, electronic) and times, 
pharmacists are better enabled to communicate effectively 
with physicians and others.39 Collaborative support for 
improved communications is needed across three levels -- 
individuals, healthcare teams and organizations (leadership 
and culture).40  Embedment of an interdisciplinary approach 
into the healthcare system can raise awareness of the value 
of cooperative teamwork and application of consistent 
patterns among health professionals to achieve positive 
patient outcomes.34,35,37 
 
More research is needed to evaluate the impact of 
socialization on healthcare work environments and quality of 
care provided to the patients.36 Effective patient-provider 
communications results in improved patient knowledge, 
adherence, satisfaction, and safety, as well as reduced 
healthcare costs.41-43 Recommendations for patient-centered 
communications are readily available,44-46 including resources 
for communicating with patients about harm.47 Despite 
strong evidence on the benefits of patient engagement in 
healthcare decisions, the practice is not mandated or perhaps 
not yet followed to a large extent in healthcare systems.48  
 
Education and Training 
Momentum is building on the need to contemporize health 
professions education and related training programs to meet 
changing population needs and prepare students in efforts to 
emphasize quality and safety, decrease errors, and utilize 
evidence-based practices and health informatics.5,49  Little is 
known on a nationwide basis about the extent of curricular 
incorporation of methods to decrease adverse events and 
improve patient safety in health professions degree 
programs.4,50,51 Descriptions of curricular aspects of patient 
Commentary PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                           2016, Vol. 7, No. 3, Article 2                        INNOVATIONS in pharmacy   3 
 
 
safety, error reduction, and quality improvement for 
individual programs are published in regard to undergraduate 
medical education,4,12,52,53 postgraduate medical training,54-56  
nursing education,33,50,57,58 pharmacy education,9,59-62 and 
interdisciplinary health education.34,63 Efforts directed toward 
integration of concepts supporting the culture of safety and 
the science of safety should involve raising awareness and 
expanding offerings, rather than major curricular revision.1 
Education and training about postmarketing surveillance, 
pharmacoepidemiology, and FDA’s role in product safety and 
adverse event reporting should be advocated.64-66  
 
The American Association of Colleges of Pharmacy (AACP) 
and FDA partnered to determine the 2010 baseline status on 
integration of the science of safety in professional degree 
curricula for pharmacy students.17,67 Findings demonstrated 
that curricula in colleges of pharmacy provided aspects of the 
science of safety, though gaps exist.17 Didactic learning and 
experiential teaching strategies can help pharmacy students 
understand the complexities involved in real-world 
environments and need for safety design considerations for 
risk identification, assessment and mitigation. To foster 
awareness of safety concerns and knowledge dissemination 
learned from adverse event reporting, novel teaching 
strategies should be incorporated in health professions 
education to help prepare students for the challenges they 
will face in practice.65 Relevant continuing education and 
lifelong learning are paramount for healthcare practitioners 
to keep knowledge and skills up-to-date. The IOM 
recommended all practicing clinicians demonstrate continued 
competency through periodic assessments.5 
 
Research 
Research programs on drug safety have focused primarily on 
sick individuals with respect to treatment of disease 
processes. New paradigms necessitate the need for enhanced 
safety considerations for both healthy subjects and patient-
subjects in research processes as novel drugs are evaluated 
for outcomes on cognitive functioning, impact on major 
organ systems, and health-related quality of life.19 
 
Improved and validated, clinically-appropriate metrics are 
needed to measure adverse drug events, which rank among 
the leading causes of iatrogenic harm to patients.68 
Development of a common hazard taxonomy in management 
and risk identification methods such as root cause analysis 
(RCA), failure modes and effects analysis (FMEA) or 
situational briefing models can help prevent the hierarchical 
structure of an organization from impeding its ability to 
achieve better patient safety models.38,61,69-71 The AHRQ 
addressed evidence–based patient safety strategies through 
commissioned reports in 200172 and updated 2013,73 with 
strong encouragement for adoption. More research is needed 
to effectuate implementation of evidence-based safety 
practices, build new tools to assess safety measures, and 
disseminate knowledge among healthcare professionals, 
payers, patients, and other audiences.74-76  
 
Through the Institute for Safe Medication Practices (ISMP) 
Medication Error Reporting Program, MedWatch, FDA 
Adverse Event Reporting System (FAERS), related vaccine 
error reporting programs or other mechanisms, healthcare 
professionals and consumers can voluntarily report adverse 
events associated with drugs, biologics, and medical 
devices.13,14  The pharmaceutical industry is mandated to 
report adverse drug events to FDA.77 Review and research on 
nationally-reported adverse events can identify causes and/or 
contributory safety concerns, strengthen monitoring, and 
generate recommendations and policies to prevent future 
occurrence. 
 
Barriers to the Implementation of Science of Safety 
Individual barriers such as poor communication abilities and 
inadequate knowledge about pharmacovigilance, error 
reporting, or research processes obstruct efforts to improve 
the science of safety.78-80 Lags in timely reporting and 
dissemination of evidence-based patient safety practices 
impede efforts to develop safer healthcare systems.81 Lack of 
information technology, insufficient standardization in error 
definition, insufficient staffing, and limited access to clinical 
data are recognized as system barriers that impede delivery 
of quality of care to patients. Culture of blame in healthcare 
systems and fear of punishment deter error reporting, 
representing additional barriers in developing the science of 
safety.33,82  While increased attention is directed to the 
science of safety regarding prescription drug products and 
biologics, less stringent regulations, oversight and evidence-
based practices exist for non-prescription drug products83 and 
compounded drug preparations.84 
 
Conclusion 
This paper describes the science of safety through a 
conceptualized process. It provides an overview on the 
lifecycle of drug/biologic approval and regulation and the 
roles played by diverse stakeholders in implementing better 
patient safety systems and measures. The need for ongoing 
education and training programs, as well as robust research, 
is underscored. This paper also emphasizes the need for 
collaborative, interdisciplinary care provision by health 
professionals and effective communications (within 
healthcare systems and via patient-provider interactions) to 
ensure optimal quality care. Collectively, these practices can 
reduce barriers and promote safer medication use. 
Developing a medication-use system based on the science of 
safety should be an aspirational goal to achieve exceptional 
levels of patient safety, quality care, and effectiveness.  
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Figure 1.  Science of Safety in Lifecycle of Drugs/Biologics 
 
 
 
The Science of Safety: A Lifecycle Approach 
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Figure 2. Major Stakeholder’s Role in the Science of Safety 
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